Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Sichuan Biokin Pharmaceutical (688506 CH)
Watchlist
53
Analysis
Health Care
•
China
Sichuan Biokin Pharmaceutical Co.,Ltd. operates as a pharmaceutical company. The Company produces children's medicine, cardiovascular drugs, anesthetics, chronic disease drugs, and more. Sichuan Biokin Pharmaceutical conducts businesses worldwide.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Sichuan Biokin Pharmaceutical Co Ltd
•
11 Aug 2026 06:37
Primer: Sichuan Biokin Pharmaceutical Co Ltd (SBP12 HK) - Aug 2026
Sichuan Biokin Pharmaceutical is a commercial-stage biopharmaceutical company at the forefront of China's rapidly growing oncology market, with...
αSK Primers
102 Views
Share
bullish
•
Sichuan Biokin Pharmaceutical Co Ltd
•
09 Aug 2026 11:02
Sichuan Biokin Pharmaceutical Co Ltd (SBP12 HK): Synthetic Expert Call Transcript (09 Aug 2026)
First-in-Class Validation & Commercial Ramp: Iza-bren (BL-B01D1) secured its first NMPA approval on June 22, 2026, for recurrent or...
αSK SmartScripts
103 Views
Share
bullish
•
Sichuan Biokin Pharmaceutical Co Ltd
•
08 Aug 2026 10:10
IPO Databook: Sichuan Biokin Pharmaceutical (HK) - Aug 2026
Sichuan Biokin Pharmaceutical Co., Ltd. is an integrated biopharmaceutical group founded in 1996, focused on developing oncology therapeutics...
αSK IPO Databooks
120 Views
Share
bearish
•
Hong Kong Exchanges and Clearing
•
19 Nov 2023 05:30
Index Rebalance & ETF Flow Recap: FRTIB, Japan, CSI300, CSI500, STAR50, WuXi XDC, Asahi
This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...
Brian Freitas
Follow
1.1k Views
Share
bearish
•
Sichuan Biokin Pharmaceutical
•
08 Apr 2026 17:15
MS-China March 2026 Rebalance: Post-Event Review
A retrospective look at the MSCI China Feb 2026 rebalance: cross-window alpha, FF/ADV bucket cuts for ADD and DELETE, and the implementation-day...
Ke Yan, CFA, FRM
Follow
301 Views
Share
1
2
3
4
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x